Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14103450 | 0.94 | — | — | |
| SCHEMBL4522780 | 0.89 | LMNA (0.42) | MCL1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL17383876 | 0.85 | — | — | |
| SCHEMBL29460411 | 0.85 | MCL1 (0.39) | MCL1LMNAPOLBALDH1A1MALT1 | |
| SCHEMBL3770232 | 0.85 | — | — | |
| SCHEMBL20801526 | 0.84 | ALDH1A1 (0.35) | MCL1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL2019977 | 0.83 | — | — | |
| SCHEMBL5634947 | 0.83 | — | — | |
| SCHEMBL24917526 | 0.83 | MCL1 (0.33) | MCL1LMNA | |
| SCHEMBL20662159 | 0.83 | LMNA (0.34) | MCL1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138000-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3778573-A1 | COMPOUND WITH ANTICANCER ACTIVITY | Kyowa Kirin Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019189778-A1 | COMPOUND WITH ANTICANCER ACTIVITY | 協和発酵キリン株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1585827-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040180906-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-16 | — | — | US | disclosed |
| US-20040176395-A1 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-09 | — | — | US | disclosed |
| US-20040171075-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| WO-2004060305-A2 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004061084-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060306-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
| US-4868296-A | 6-(1-carbamoyl-1-hydroxymethyl) penicillanic acid derivatives | PFIZER INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4797394-A | 6-(1-carbamoyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0220939-A1 | 6-(1-Carbamoyl-1-hydroxymethyl)penicillanic-acid derivatives | PFIZER INC. (US) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | MCL1 728/4885LMNA 4513/4885POLB 2697/4885 |
| US-20040180906-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MCL1 2636/4885LMNA 3791/4885POLB 3484/4885 |
| US-20040176395-A1 | Anti-cancer medicaments | ABL1, ABL2, SRC | MCL1 26/4885LMNA 4092/4885POLB 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.